David D. Meek - 16 Jun 2026 Form 4 Insider Report for Cullinan Therapeutics, Inc. (CGEM)

Reporting relationship: Director
Issuer ticker: CGEM
Reported as of: 16 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Jun 2026, 17:00:19 UTC
Prior SEC filing: 12 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Jacquelyn Sumer, Attorney-in-Fact

Key filing fact

David D. Meek filed Form 4 for Cullinan Therapeutics, Inc. (CGEM) on 18 Jun 2026.

Key facts

This page summarizes David D. Meek's Form 4 filing for Cullinan Therapeutics, Inc. (CGEM).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 18 Jun 2026, 17:00.

Change

Previous filing in this sequence was filed on 12 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001555337 Primary reporting owner

Meek David D.

Relationship: Director
Address: C/O CULLINAN THERAPEUTICS, INC., ONE MAIN STREET, SUITE 1350, CAMBRIDGE
Signature: /s/ Jacquelyn Sumer, Attorney-in-Fact
Signature date: 18 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CGEM transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +25,319
Change %
Price: $0.000000^*
Shares after: 25,319
Date: 16 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 25,319
Exercise price: $13.55
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option represents a right to purchase a total of 25,319 shares of the Issuer's Common Stock, which shall vest in full on the earlier of (i) June 16, 2027 or (ii) the date of the Issuer's next annual meeting, subject to the Reporting Person's continued service as a director on such vesting date.